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Background: Persistent and/or recurrent inflammatory processes are the main factor leading to multiple sclerosis
(MS) lesions. The composite ultramicronized palmitoylethanolamide, an endogenous N-acylethanolamine, combined
with the flavonoid luteolin, PEALut, have been found to exert neuroprotective activities in experimental models of
spinal and brain injury and Alzheimer disease, as well as a clinical improvement in human stroke patients.
Furthermore, PEALut enhances the expression of different myelin proteins in oligodendrocyte progenitor cells
suggesting that this composite might have protective effects in MS experimental models.
Methods: The mouse model of experimental autoimmune encephalomyelitis (EAE) based on active immunization
with a fragment of myelin oligodendrocyte glycoprotein (MOG35-55) was used. The daily assessment of clinical score
and the expression of serum amyloid A (SAA1), proinflammatory cytokines TNF-α, IL-1β, IFN-γ, and NLRP3
inflammasome, as well as TLR2, Fpr2, CD137, CD3-γ, and TCR-ζ chain, heterodimers that form T cell surface
glycoprotein (TCR), and cannabinoid receptors CB1, CB2, and MBP, were evaluated in the brainstem and cerebellum
at different postimmunization days (PIDs).
Results: Vehicle-MOG35-55-immunized (MOG35-55) mice developed ascending paralysis which peaked several days
later and persisted until the end of the experiment. PEALut, given intraperitoneally daily starting on day 11 post-
immunization, dose-dependently improved clinical score over the range 0.1–5 mg/kg. The mRNA expression of
SAA1, TNF-α, IL-1β, IFN-γ, and NLRP3 were significantly increased in MOG35-55 mice at 14 PID. In MOG35-55 mice
treated with 5 mg /kg PEALut, the increase of SAA1, TNF- α, IL-1β, and IFN-γ transcripts at 14 PID was statistically
downregulated as compared to vehicle-MOG35-55 mice (p < 0.05).
The expression of TLR2, Fpr2, CD137, CD3-γ, TCR-ζ chain, and CB2 receptors showed a significant upregulation in
vehicle-MOG35-55 mice at 14 PID. Instead, CB1 and MBP transcripts have not changed in expression at any time. In
MOG/PEALut-treated mice, TLR2, Fpr2, CD137, CD3-γ, TCR-ζ chain, and CB2 mRNAs were significantly
downregulated as compared to vehicle MOG35-55 mice.
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Conclusions: The present results demonstrate that the intraperitoneal administration of the composite PEALut
significantly reduces the development of clinical signs in the MOG35-55 model of EAE. The dose-dependent
improvement of clinical score induced by PEALut was associated with a reduction in transcript expression of the
acute-phase protein SAA1, TNF-α, IL-1β, IFN-γ, and NLRP3 proinflammatory proteins and TLR2, Fpr2, CD137, CD3-γ,
TCR-ζ chain, and CB2 receptors.
Keywords: Multiple sclerosis, EAE, Acute phase response, PEALutBackground
Multiple sclerosis (MS) is one of the world’s most com-
mon neurologic disorders, and in many countries, it is
the leading cause of non-traumatic neurologic disability
in young adults [1]: it is estimated that MS affects ap-
proximately 2.3 million people worldwide [1, 2], with in-
creased incidence in female [2]. Although widely
believed to be immune-mediated and pathologically at-
tributable to myelin-specific autoreactive CD4+ T cells,
the humoral autoimmune response in MS is probably
not restricted to myelin but affects the entire brain. The
complex heterogeneity of MS is proven by the finding
that auto-antibodies are formed against different CNS
cell types, including neurons, oligodendrocytes, astro-
cytes, and immune cells [3]. Effector cells of both the in-
nate and adaptive immune systems, e.g., microglia,
activated macrophages, mast cells, and B and T lympho-
cytes, are all known to influence the pathogenesis of MS.
Persistent and/or recurrent inflammatory processes are
the main factor leading to the loss of neuroaxonal
homeostasis and the onset of neurodegeneration that af-
fects both white and gray matter [2].
This complex physiopathogenesis, with inflammatory
and degenerative processes coexisting in different de-
grees and proportions, makes the optimization of the
pharmacological therapy challenging, particularly for
progressive forms of MS. Moreover, the presence of sev-
eral symptoms such as spasticity, fatigue, ataxia and
tremor, and bladder dysfunctions require a multidiscip-
linary approach and careful treatment selection.
The endocannabinoid system and related bioactive
lipids participate in multiple physiological processes that
include metabolic and immune regulatory mechanisms
also contributing to the maintenance of the organism’s
homeostasis [4]. Among endocannabinoid related bio-
active lipids, N-acylethanolamines (NAEs) have similar
chemical structures to endocannabinoids (ECs), but they
do not show affinity for cannabinoid receptors. However,
they do compete with ECs for metabolizing enzymes
and thus can intensify the action of ECs by reducing
their degradation (“entourage” effect) [5, 6]. The NAE
functions are additionally mediated via different non-
cannabinoid receptors and ion channels including vari-
ous GPCRs (e.g., GPR55, GPR119), peroxisomeproliferator-activated receptors (PPARs), and transient
receptor potential (TRP) channels (e.g., vanilloid recep-
tor TRPV1) [7–9]. Among NAEs, N-
palmitoylethanolamine (palmitoylethanolamide, PEA) is
abundant in the CNS and conspicuously produced by
neurons and glial cells [10]. Evidence indicates that PEA
is an important anti-inflammatory, analgesic, and neuro-
protective mediator acting at several molecular targets
in both central and peripheral nervous systems [9]. In
addition to large evidence deriving from experimental
studies, in recent years, several clinical studies have con-
firmed the antinflammatory and neuroprotective proper-
ties of PEA in humans [9, 11]. Most clinical trials with
PEA were performed with formulations whose particles
have been subjected to the so-called fluid jet
micronization process. This allows to obtain particles
with a defined size profile being completely different and
statistically lower (6–10 μm at most) in comparison to
naïve PEA (in the 100–700 μm range). Moreover, the
ultramicronization process yields a different crystalline
structure with higher energy content. The smaller par-
ticle size (with higher surface-to-volume ratio) combined
with increased potential energy contributes to better
solubility. These characteristics result in better diffusion
and distribution of micronized and ultramicronized
PEA compared to the naïve form, and thus superior bio-
logical efficacy [9, 12]. Among formulations containing
ultramicronized PEA, PEALut also contains luteolin (3′,
4′,5,7-tetrahydroxyflavone, Lut) [13].
Lut is a flavonoid present in many plants, including
various fruits, vegetables, and medicinal herbs. Lut and
its congeners exhibit antinflammatory, antioxidant, neu-
roprotective, and anti-carcinogenic activities and have
been reported to potentially contribute to the treatment
of MS [14].
In addition, Lut has been also shown to improve the
morphology of PEA: naïve PEA shows a morphology
characterized by large flat crystals; the coprecipitation of
PEA with very small quantities of Lut stabilizes the mi-
croparticles inhibiting PEA crystallization process
through creation of hydrogen bonds between PEA and
Lut [15]. The greater molecular stability of PEA in the
presence of Lut likely contributes to the high recovery of
neurological outcome observed in experimental models
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mer disease [16–18], as well as the clinical improvement
observed in human stroke patients [19]. Furthermore,
our previous findings showed that PEALut enhances
oligodendrocyte progenitor cell (OPC) morphological
complexity along with the expression of different myelin
proteins [20, 21]. In OPCs subjected to tumor necrosis
factor alpha (TNF-α) treatment, PEALut reduces the
acute-phase protein serum amyloid A1 (SAA1) expres-
sion [22], a gene coding for SAA protein that was found
to be elevated in peripheral blood of patients with re-
lapsing–remitting MS over a 3-month period [23]. This
raises the possibility that the composite might have pro-
tective effects in MS experimental models. To verify this
hypothesis, the mouse model of experimental auto-
immune encephalomyelitis (EAE) based on active
immunization with a fragment of myelin oligodendro-
cyte glycoprotein (MOG35-55) was used. The daily assess-
ment of clinical score and the expression of SAA1,
proinfiammatory cytokines TNF-α, IL-1β, and IFN-γ,
and NLRP3 inflammasome as well as TLR2, Fpr2, CD3-
γ, TCR- ζ chain, CD137, and cannabinoid receptors CB1,
CB2, and myelin basic protein (MBP) were evaluated in
the brainstem and cerebellum at different postimmuni-
zation times (postimmunization days, PIDs).
Methods
EAE model and clinical neurological scoring
EAE model and clinical neurological scoring were per-
formed as previously reported [24]. Animals were habitu-
ated for at least 1 week before the experiment and then
were immunized. The animals were housed under con-
trolled environmental conditions (LD 12:12 h regime in
air-conditioned rooms, 22 ± 2 °C, 55 ± 10% humidity) and
allowed free access to food and water throughout the ex-
periment. To minimize stress factors and to accustom the
animals to the experimenter, during the week preceding
immunization, mice were gently handled by the same ex-
perimenter on alternate days (1 min per mouse/day). The
number of animals for each experimental group and for
each analyzed time was 8, if not otherwise specified.
All experiments were conducted in compliance with
EU guidelines for the care and use of laboratory animals
and those of the Italian Ministry of Health (D.Lg. 26/
2014). The study was approved by the Institutional Re-
view Board for Animal Research (Organismo Preposto al
Benessere Animale, OPBA) of the University of Padua
and by the Italian Ministry of Health (autorization num-
ber 65/2017-PR).
Induction of EAE and monitoring of the course of the
disease
For induction of EAE, Hooke Kits™ EAE Emulsion
(Hooke Laboratiores, Lawrence, Massachusetts USA)were used. C57BL/6 mice were immunized by adminis-
tration of MOG35–55/Freund’s complete adjuvant (FCA)
emulsion. Emulsion (200 μl) was administered subcuta-
neously at two sites (100 μl between the ears and 100 μl
in hind flank). Each mouse was also injected intraperito-
neally with 100 μl of Bordetella pertussis toxin (PTx)
dissolved in phosphate-buffered saline (PBS) (Hooke
Laboratiores) 4 h after the administration of the
emulsion and again 24 h later. PTx enhances EAE devel-
opment by providing additional adjuvant and is believed
to facilitate entrance of autoimmune T cells into the
CNS. Control mice were injected with CFA and PTx
only (Hooke Control Kits™, Hooke Laboratiores, USA).
All mice were weighed weekly and examined daily for
the neurological symptoms of EAE, scored as reported
in Table 1.Compound treatment
PEALut for treatment was prepared as a 9 mg/ml stock
solution in aqueous 10% (w/v) Pluronic F-68 and soni-
cated for 20 min in a sonicating water bath. The PEALut
suspension was then diluted into PBS to reach 0.5 mg/
ml (final concentration of Pluronic F-68: 0.55%). Mice
received intraperitoneally 200 μl of either 0.55% Pluronic
F-68 or 0.5 mg/ml PEALut to achieve a dose of 5 mg/kg
body weight (assuming an average weight of 20 g per
mouse). For lower doses, the PEALut stock solution was
diluted accordingly in 0.55% Pluronic F-68, in order to
maintain constant the concentration of carrier adminis-
tered. PEALut was administered on a daily basis and at
the same time each day. Clinical score was determined
as described above.
For the dose response study, PEALut was administered
at 0.1, 1, and 5 mg/kg starting from 11 PID until 27 PID.
Mice (8 for each group) were sacrificed on 28 PID. For
quantification of mRNAs, the dose of 5 mg/kg PEALut
was employed and mice (6 for each group) were sacri-
ficed at 7, 14, and 21 PIDs. All the mRNA expressions
were evaluated on mice that received PEALut starting at
11 PID.
In a separate experiment, PEALut (5 mg/kg) treatment
was started at 2 PID (8 for each group). Control animals
were treated with PeaLut vehicle (Veh).Tissue collection and processing
Animals of different experimental groups were sacrificed
by cervical dislocation. Animals used for the evaluation
of mRNAs were sacrificed before the onset of clinical
score (7 PID), during the increase of clinical score (14
PID), and when the disease progression was ceased (21
PID). The brainstem and cerebellum were rapidly dis-
sected out and suddenly frozen on dry ice. Tissues were
stored at − 80 °C until processed for RNA extraction.
Table 1 EAE neurological scores
Score Clinical signs
0 No sign of disease; the tail is erect,
and locomotor activity is intact
0.5 Tail is erect, but the tip is limp
1.0 Tail is limp but signs of
movement remain. Locomotor
activity is slightly impaired and
hind legs are extended
1.5 Tail is limp and one of two hind
legs appears to be weak.
Balance is slightly impaired
2.0 Tail is limp with no signs of
movement; both hind legs
are weak. Locomotor activity
is impaired, and mice show poor
balance and may drag a hind leg.
Even in the absence of
uncoordinated movement,
the mouse presents with
inclined head and poor balance
2.5 Tail is limp, both hind legs
are weak; one hind leg lacks
movement or may be dragging
3.0 Tail is limp and both hind limbs
are completely paralyzed. Locomotor
activity is clearly impaired
3.5 Tail is limp and both hind limbs
are completely paralyzed, partial
front leg paralysis. Locomotor activity is
clearly impaired. When turned on its side,
mouse is unable to right itself
4.0 Tail is limp, complete hind leg, and
partial front leg paralysis. In cases
where the mouse reaches a score
4 for 2 consecutive days,
euthanasia is recommended
4.5 Complete hind and partial front
leg paralysis, no movement around
the cage. Mouse is not alert.
Euthanasia is recommended
5.0 Mouse is dead
Table 2 Primer sequences used for reverse transcription
Gene Forward (5′→ 3′) Reverse (5′→ 3′)
GAPDH TGGTGAAGGTC
GGTGTGAAC
AATGAAGGGGTC
GTTGATGG
SAA1 ACACTGACATGAAGG
AAGCTAAC
GACCCCTTTGAGC
AGCATCAT
TNF-α CAAGTGGAGGAG
CAGCTGGA
CATCGGCTGGCA
CCACTAGT
IL-1β CTGGTGTGTGACG
TTCCCATTA
CCGACAGCAC
GAGGCTTT
IFN-γ ACATGAAAATCCTGCAGAGCCA TCAGGTGTGATTCA
ATGACGCT
NLRP3 CCTGACCCAAA
CCCACCAGT
AGACCTCCCCA
ATGTGCTCG
TLR2 GCGGTCACTGG
CAGGAGA
CATCTTTTCCACTTC
TAGGTCGC
Fpr2 TCCTGGGCTCAA
ACTGATGA
GCAACAATTGACA
TGGGCAT
CD137 TCTGTGCTTAAGA
CCGGGACC
ATGGTGGTACTGGGA
GAGAAGC
CD3γ AGTGGCTTAAAG
ACGGGAGC
CCTCGAGGGTCTT
TGGCATTG
TCR ζ chain GAGCTTTGGTCTGCT
GGATCCC
ACAGGGCTGTGATGA
TGACTCC
CB1 GATCTTAGACGGC
CTTGCAGA
AATGTCATTTGAGCC
CACGTAG
CB2 ACAGCTCCAGTAGAA
GAAGCCA
TGAACTCCAAGCCA
CCGTTG
MBP TCCGAGGAGAGT
GTGGGTTT
TGGAACGATCTGG
AGGGTTT
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and to other proteins involved in MOG35-55-induced
clinical alterations.
Quantitative real-time polymerase chain reaction (q-PCR)
Total RNA was extracted from brainstem and cerebel-
lum by QIAzol (Quiagen), according to the manufac-
turer’s instructions. RNA quantity and purity were
determined by NanoDrop 2000 (Thermo Scientific)
(A260/280 ratio > 1.8). Reverse transcription was per-
formed with Superscript IV reverse transcriptase
(Thermo Scientific). The q-PCR reaction was performed
as described previously [22]. Primer sequences are listed
in Table 2. Amounts of each gene product were calcu-
lated using linear regression analysis from standard
curves, demonstrating amplification efficiencies ranging
from 90 to 100%. Dissociation curves were generated foreach primer pair, showing single product amplification.
Data are normalized to GAPDH mRNA level.
Statistical analysis
Data are given as mean ± SEM at each time point. Statis-
tical analyses to determine group differences were per-
formed by ANOVA (Prism 7.0, Graphpad software)
followed by Bonferroni multiple comparison test or
Newman-Keuls for comparisons involving more than
two data groups.
Results
PEALut treatment ameliorates clinical severity of EAE
mice
All groups of mice started to develop clinical signs, in-
cluding tail and hindlimb paralysis, on days 8–9 after
MOG35-55 immunization. Veh-treated mice developed a
typical course of chronic EAE, as evidenced by ascend-
ing paralysis which peaked several days later and then
persisted until the end of the experiment (Figs. 1 and 2).
The treatment with PEALut to MOG35-55 mice starting
at 11 PID elicited a significant reduction in clinical
symptoms (p = 0.002; repeated measure ANOVA). Fur-
thermore, the PEALut induced a dose-dependent
Fig. 1 Dose-dependent effect of PEALut, started at 11 PID, on neurologic score severity in MOG35-55 immunized mice. All mice were immunized
with MOG35-55 and treated with PEALut at doses of 0.1, 1, and 5mg/kg or corresponding Veh. PEALut treatments started at 11 PID. Data are
presented as means ± SD. n = 8 for each experimental group. *p = 0.04; **p = 0.004. Newman-Keuls post hoc test
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0.1 mg/kg failed to affect EAE course, while 1 and 5mg/
kg significantly attenuated the paralysis of EAE during
the observation period as compared to the Veh treated
group (p = 0.022 and p = 0.004, respectively, Newman-
Keuls post hoc test; Fig. 1). The reduction in clinical
scores elicited by 5 mg/kg PEALut was significantly
higher as compared to 1 mg/kg (p = 0.04). A significant
PEALut-induced reduction in neurological scores, with-
out a complete inhibition of the immune response in-
duced by MOG35-55, was also observed when PEALut
treatment (5 mg/kg) started at 2 PID (p = 0.04, repeated
measure ANOVA, Fig. 2).
PEALut treatment starting at 11 PID reduces the
inflammatory response after MOG35-55 peptide
immunization
The mRNA expression of the acute-phase SAA1, proin-
flammatory cytokines TNF-α, IL1-β, and IFN-γ, and
NLRP3 inflammasome were evaluated in the brainstem
and cerebellum at 7, 14, and 21 PIDs. Non-immunized
mice were used as control.SAA1 mRNA level was low in control mice in both
the brainstem and cerebellum at all analyzed times
(Fig. 3). In Veh-MOG35-55 mice, a significant increase of
SAA1 mRNA, as compared to non-immunized controls,
was observed in both the brainstem and cerebellum at
14 PID (p < 0.001 and p < 0.01, respectively. Bonferroni
post hoc test; Fig. 3) but not at 21 PID. In MOG35-55
mice treated with 5 mg/kg PEALut, the increase of
SAA1 mRNA observed at 14 PID was statistically down-
regulated as compared to Veh-MOG35-55 mice (p <
0.05; Bonferroni post hoc test; Fig. 3).
TNF-α, IL-1β, and IFN-γ transcripts were expressed at
low level in both the brainstem and cerebellum in Veh-
treated animals. A significant mRNA upregulation of all
analyzed cytokines was observed in Veh-MOG35-55 mice
at 14 PID, but not at 7 and 21 PID, in both the brainstem
and cerebellum (p < 0.001 for TNF-α and IFN-γ; p < 0.05
for IL-1β; Bonferroni post hoc test). In MOG/PEALut-
treated mice, the increase in TNF-α, IL-1β, and IFN-γ
mRNAs was significantly reduced as compared to
MOG35-55 mice receiving (p < 0.05; Bonferroni post hoc
test, Table 3).
Fig. 2 Effect of PEALut treatment, started at 2 PID, on neurologic score severity in MOG35-55 immunized mice. All mice were immunized with
MOG35-55 and treated with PEALut at 5 mg/kg or corresponding Veh starting at 2 PID. Data are presented as means ± SD. n = 8 for each
experimental group. The PEALut treatment induced a significant reduction in score severity (p = 0.04, repeated measure ANOVA)
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in MOG35-55 immunized-mice at 14 PID (p < 0.001; Bon-
ferroni post hoc test), and such increase was still signifi-
cant at 21 PID in the cerebellum (Table 3). In MOG/
PEALut-treated mice, there was a downregulation of
NLRP3 mRNA in the cerebellum at 14 PID.
MOG35-55 peptide and PEALut treatment regulate the
expression of selected receptors involved in inflammation
in EAE mice
The expression of TLR2, Fpr2, CD3-γ, TCR-ζ chain,
CD137, CB1, CB2, and MBP mRNAs were evaluated in the
brainstem and cerebellum at 7, 14, and 21 PIDs. In the
former area, TLR2, Fpr2, CD3-γ, TCR-ζ chain, CD137, and
CB2 mRNAs showed a significant upregulation in Veh-
MOG35-55 mice at 14 PID, whereas only CD3-γ, TCR-ζ
chain, and CB2 were still upregulated at 21 PID. In the cere-
bellum, TLR2, Fpr2, CD3-γ, TCR-ζ chain, CD137, and CB2
mRNAs were upregulated at 14 PID and the expression of
TLR2, CD3-γ, TCR-ζ chain, and CB2 mRNAs persisted at
21 PID (Table 4). CB1 and MBP transcripts have not chan-
ged in expression at any time. In MOG/PEALut-treated
mice, CD3-γ, TCR-ζ chain, CD137, TLR2, and CB2 mRNAs
were significantly downregulated as compared to Veh-
MOG35-55 mice at 14 PID in both brain areas (Table 4).
Discussion
The present results demonstrate that the intraperitone-
ally administration of the composite PEALutsignificantly reduces the development of clinical signs in
the MOG35-55 model of EAE. The dose-dependent im-
provement of clinical score induced by PEALut is associ-
ated with a reduction in transcript expression of the
acute-phase protein SAA1, the pro-inflammatory cyto-
kines TNF-α, IL-1β, IFN-γ, and NLRP3, and of receptors
TLR2, Fpr2, CD137, CD3-γ, TCR-ζ chain, and CB2.
For dose-response evaluation, PEALut administration
was initiated at 11 PID, at the first signs of sickness. At
this time, the T cell priming is not prevented, and it is
possible to assess just the subsequent decrease of the
disease (semi-therapeutic treatment). A protective effect
was also observed when the PEALut treatment was
started at 2 PID. In this condition, PEALut attenuates
the clinical symptoms induced by MOG35-55. This sug-
gest that the reduced clinical symptoms could be due to
a reduced T cell infiltration into the CNS also indicated
by CD3-γ and TCR-ζ chain mRNA reduction in the
PEALut-treated group.
In a previous study [25], it was demonstrated that 5
mg/kg PEA reduced the severity of clinical scores of
EAE. In the present paper, using the same EAE protocol,
but administering different doses of a composite con-
taining PEA, PEALut, we obtained a reduction in neuro-
logical scores that resembles what was previously
reported [25]. The results of our study confirm the anti-
inflammatory effects of PEALut, which resembles to that
of PEA alone. In contrast, in our in vitro studies, PEA-
Lut regulation of gene expression in oligodendrocyte
Fig. 3 SAA1 mRNA expression in MOG35-55-mice treated with Veh or PEALut. Mice were treated with Veh, MOG/Veh, or MOG/PEALut for 7, 14,
and 21 days. Veh or PEALut treatment started at 11 PID. SAA1 mRNA values are reported as mean ± SEM. a Brainstem, b cerebellum. Data are
shown as relative expression of Veh values normalized to 1. n = 6 mice for each group. °°p < 0.01, °°°p < 0.001 compared with the Veh-treated
group. *p < 0.05 compared with the MOG/Veh
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ponents alone, thus suggesting a putative novel effect of
PEALut on myelination processes [20]. Unfortunately, in
our in vivo experimental conditions, in both the brain-
stem and cerebellum, we did not observe any change in
gene codifying myelin proteins at any time (Table 4).
This did not allow the evaluation of the PEALut effecton myelination. To test a potential PEALut remyelinat-
ing effect, it should be more convenient to use the clas-
sical and well established cuprizone-mediated model of
demyelination/remyelination.
In addition to neurological scores, in the present
study, we examined gene expression and receptors in-
volved in inflammation in the brainstem and cerebellum.
Table 3 Proinflammatory protein mRNAs expression in brainstem and cerebellum of MOG35-55 immunized mice treated with Veh or
PEALut
Brainstem Cerebellum
PID PID
7 14 21 7 14 21
TNF-α/GADPH Veh 1.0 ± 0.1 1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.2
MOG/Veh 2.5 ± 0.3 106.4 ± 33.3°°° 21.6 ± 6.5 1.6 ± 0.1 71.7 ± 19.7°°° 32.2 ± 14.1
MOG/PEALut 2.4 ± 0.4 52.6 ± 21.9* 15.9 ± 4.5 2.0 ± 0.2 31.9 ± 11.4** 16.5 ± 4.6
IL1-β/GADPH Veh 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.5 1.0 ± 0.5
MOG/Veh 2.4 ± 0.6 330.2 ± 77.8°°° 31.5 ± 6.9 2.1 ± 0.3 123.0 ± 78.6° 21.8 ± 8.8
MOG/PEALut 4.7 ± 2.0 174.7 ± 65.8** 23.7 ± 6.5 4.0 ± 0.8 18.8 ± 12.2* 14.8 ± 6.8
INFγ/GADPH Veh 1.0 ± 0.2 1.0 ± 0.5 1.0 ± 0.4 1.0 ± 0.2 1.0 ± 0.4 1.0 ± 0.2
MOG/Veh 1.0 ± 0.3 115.2 ± 0.5°°° 19.2 ± 4.7 1.7 ± 0.5 37.8 ± 15.7°° 27.8 ± 8.1
MOG/PEALut 1.4 ± 0.3 35.7 ± 17.2** 19.3 ± 7.7 1.0 ± 0.1 6.9 ± 1.8* 22.5 ± 10.4
NLRP3/GADPH Veh 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
MOG/Veh 0.7 ± 0.0 11.2 ± 1.4°°° 3.3 ± 0.6 0.7 ± 0.1 7.2 ± 2.0°°° 4.4 ± 0.8°
MOG/PEALut 1.0 ± 0.2 6.9 ± 2.2** 2.2 ± 0.6 0.9 ± 0.1 2.9 ± 0.6** 2.9 ± 0.6
Mice were treated with Veh, MOG/Veh, or MOG/PEALut for 7, 14, and 21 days. Veh or PEALut treatments started at 11 PID. TNF-α, IL-1β, INFγ, and NLRP3 mRNAs
values are reported as mean ± SEM. Data are shown as relative expression of Veh-treated values normalized to 1. n = 6 mice for each group. °p < 0.05, °°p < 0.01,
and °°°p < 0.001 compared with the Veh-treated group. *p < 0.05 and **p < 0.01 compared with the MOG/Veh
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the time analyzing a large number of inflammatory gene
markers (such as, TNF-α, IL1-β, INF-γ, SAA1, and
NLRP3) and the expression of selected receptors in-
volved in inflammation (such as TLR2, Fpr2, CD3-γ,
TCR-ζ chain, and CB2).
In Rahimi’s paper [25], the TNF-α, IFN-β, and IL-17
gene expression was examined only at 28 PID; in their
experimental conditions, these genes were still upregu-
lated in MOG35-55-treated animals. In our conditions,
the gene expression was evaluated at 7, 14, and 21 PID.
At 14 PID, the expression of all inflammation-related
genes was remarkably increased in both the brainstem
and cerebellum and their expression was significantly re-
duced by PEALut. At 21 PID, there was no longer upreg-
ulation of inflammatory gene markers induced by
MOG35-55-immunization; in fact, all the genes examined
were not significantly different from the control animals.
PEALut has been shown to act as protective agent in
different experimental models of CNS diseases [16, 19,
26]. Its activity has been shown to be superior to
ultramicronized-PEA [17]. The active molecules of com-
posite, PEA and Lut, have complementary and additive
pharmacological activities, due to the ability to interact
with different targets involved in the inflammatory re-
sponse [27, 28]. PEA is endowed with important neuro-
protective, anti-inflammatory, and analgesic actions. The
peroxisome proliferator-activated receptor (PPAR)-α is
the molecular target that directly mediates some of the
neuroprotective, anti-inflammatory, and analgesic effects
of PEA [6]. Indirect mechanisms of action for PEA hasalso demonstrated that PEA potentiates anandamide ac-
tions at cannabinoid receptors (while itself having no ap-
preciable affinity for either CB1 or CB2 receptors) and
anandamide desensitization of transient receptor poten-
tial cation channel subfamily V member 1 (TRPV1)
channels (“entourage” effects). Lut is a widespread fla-
vone known to have antioxidant and cytoprotective
properties related to nuclear factor erythroid 2-related
factor 2-(Nrf2) pathway. Extensive in vitro and in vivo
investigations have underlined that Lut exhibits benefi-
cial neuroprotective properties via different mechanisms
[28]. Importantly, Lut has been shown to improve the
morphology of PEA: naïve PEA shows a morphology
characterized by large flat crystals, and the presence of
very small quantities of Lut stabilizes the microparticles
inhibiting PEA crystallization process [15]. The
stabilization of PEA by the addition of Lut together with
the combination of two different active molecules make
PEALut an interesting multi-target product with high
potentiality to tackle the chronic complex condition af-
fecting CNS. The reduction in clinical signs in EAE
MOG35-55 model alongside the decrease of the expres-
sion of different transcripts involved in the neuroinflam-
mation suggests that PEALut might have protective
effects in MS, as observed in other CNS diseases.
To identify possible mechanisms underlying PEALut-
induced protection in EAE mice, we evaluated the ex-
pression of genes coding for inflammatory proteins, i.e.,
SAA1, TNF-α, IL-1β, IFN-γ, and NLRP3. PEALut has
been shown to regulate inflammatory processes by
modulating the production of cytokines in different CNS
Table 4 Expression of TLR2, Fpr2, CD3-γ, TCR-ζ chain, CD137, CB1, CB2, and MBP mRNAs in the brainstem and cerebellum of
MOG35-55 immunized mice treated with Veh or PEALut
Brainstem Cerebellum
PID PID
7 14 21 7 14 21
TLR2/GADPH Veh 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.4 1.0 ± 0.3
MOG/Veh 0.7 ± 0.2 12.0 ± 2.8°°° 4.6 ± 0.8 0.7 ± 0.0 17.3 ± 7.6°° 16.2 ± 6.6°
MOG/PEALut 1.0 ± 0.3 6.8 ± 1.9* 3.2 ± 0.6 0.8 ± 0.4 2.6 ± 0.7* 9.7 ± 4.8
Fpr2/GADPH Veh 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.4 1.0 ± 0.2 1.0 ± 0.1
MOG/Veh 1.4 ± 0.5 45.6 ± 11.8°°° 8.0 ± 2.8 1.3 ± 0.3 50.7 ± 26.2°° 32.3 ± 13.0
MOG/PEALut 1.6 ± 0.5 24.6 ± 9.1* 5.1 ± 1.4 1.9 ± 0.2 22.6 ± 11.2 17.3 ± 4.1
CD3γ/GADPH CTRL 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1
MOG/Veh 1.2 ± 0.6 72.7 ± 9.1°°° 44.6 ± 11.4°°° 1.5 ± 0.4 140.4 ± 72.2°° 151.0 ± 40.7°°
MOG/PEALut 1.3 ± 0.3 35.2 ± 14.4** 31.8 ± 8.8 0.9 ± 0.3 31.0 ± 13.8* 105.7 ± 33.9
TCR-ζchain/GADPH CTRL 1.0 ± 0.3 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.4 1.0 ± 0.1 1.0 ± 0.1
MOG/Veh 0.9 ± 0.2 45.1 ± 8.0°°° 19.3 ± 4.6°° 1.4 ± 0.3 10.6 ± 4.5°° 8.5 ± 1.9°
MOG/PEALut 0.8 ± 0.2 19.2 ± 7.5*** 13.1 ± 3.3 1.4 ± 0.2 3.2 ± 1.1* 7.1 ± 2.2
CD137/GADPH Veh 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1
MOG/Veh 1.0 ± 0.0 140.7 ± 47.0°°° 11.9 ± 2.6 1.4 ± 0.0 27.9 ± 13.4°°° 7.3 ± 1.4
MOG/PEALut 1.2 ± 0.0 50.9 ± 20.3** 9.6 ± 2.2 1.8 ± 0.4 5.9 ± 1.2** 6.0 ± 1.4
CB2/GADPH Veh 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.3 1.0 ± 0.0 1.0 ± 0.3 1.0 ± 0.2
MOG/Veh 1.2 ± 0.1 19.0 ± 5.7°°° 7.4 ± 2.0°° 0.9 ± 0.1 8.1 ± 2.8°°° 7.5 ± 1.9°°
MOG/PEALut 1.5 ± 0.1 6.5 ± 2.5** 6.3 ± 2.3 1.5 ± 0.3 2.9 ± 0.5* 5.7 ± 1.8
CB1/GADPH Veh 1.0 ± 0.2 1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.5 1.0 ± 0.2 1.0 ± 0.1
MOG/Veh 0.8 ± 0.2 1.1 ± 0.3 1.2 ± 0.3 1.0 ± 0.2 0.9 ± 0.2 1.1 ± 0.1
MOG/PEALut 0.8 ± 0.1 1.3 ± 0.5 1.1 ± 0.3 1.6 ± 0.4 1.1 ± 0.3 0.9 ± 0.1
MBP/GADPH CTRL 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.0 1.0 ± 0.1 1.0 ± 0.1
MOG/Veh 1.1 ± 0.0 0.9 ± 0.0 0.8 ± 0.0 0.8 ± 0.1 0.8 ± 0.2 1.1 ± 0.1
MOG/PEALut 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 01 1.0 ± 0.1 0.8 ± 0.1 0.9 ± 0.0
Mice were treated with Veh, MOG/Veh, or MOG/PEALut for 7, 14, and 21 days. Veh or PEALut treatments started at 11 PID. TLR2, Fpr2, CD3γ, TCR-ζ chain, CD137,
CB1, CB2, and MBP mRNA values are reported as mean ± SEM. n = 6 mice for each group. Data are shown as relative expression of Veh-treated values normalized
to 1. n = 6 mice for each group. °p < 0.05, °°p < 0.01, and °°°p < 0.001 compared with the Veh-treated group. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with
the MOG/Veh
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a modulation of NF-κB activation [17, 26], and the
present data extend the effect to a condition that
summarize many aspects of MS. Moreover, this is the
first evidence concerning the regulation of NLRP3 ex-
pression by a NAE derivative in CNS neuroinflamma-
tion. The NLRP3 has been reported to be involved in
the development of MS through the secretion of IL-1β
and IL-18 [29], and its pharmacological inhibition has
been regarded as a potential target for the treatment of
MS [30]. Enhanced expression of NLRP3 is known to
occur in response to NF-κB activation [31]. Since PEA-
Lut has been reported to limit NF-κB activation [17, 26],
the PEALut-induced NLRP3 mRNA decrease might be a
consequence of the modulation of NF-κB activation.
Further studies are necessary to establish a potential dir-
ect action of PEALut on NLRP3 expression.In our study, PEALut also elicited a reduced SAA1 ex-
pression. In our knowledge, this is the first evidence
concerning the ability of the composite PEALut to regu-
late SAA1 mRNA expression in two cerebral areas in-
volved in EAE development. Interestingly, PEALut has
been found to significantly limit the rise of SAA1 mRNA
expression in oligodendrocyte progenitor cells subjected
to a 1-week exposure to TNF-α [22]. SAA1 is an acute
phase protein, known to be synthesized mainly by hepa-
tocytes in response to cytokines and other regulatory
factors. These proteins mobilize the leukocyte popula-
tion to neutralize pathogens, while simultaneously initi-
ate the repair processes to restore normal function and
limit secondary inflammatory damage [32].
SAA protein was found to be elevated in peripheral
blood of patients with relapsing–remitting MS over a 3-
month period [23]. In chronic-relapsing (CR) EAE
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acute phase was recently reported [33]. In CR-EAE,
SAA1 mRNA was found to be significantly elevated in
the liver in mice before the onset of clinical signs. In the
present study, by using the EAE MOG35-55 model, we
find that SAA1 mRNA is also significantly increased in
the brainstem and cerebellum in the symptomatic phase
of the disease. Since SAA1 mRNA was not measured
immediately before the symptomatic phase, it is not
clear whether its production preceded the onset of
neurological signs as observed in the liver of CR-EAE
mice. SAA1 mRNA transcription is constitutive in hu-
man and mouse brain [34–36]. Pyramidal neurons of the
cerebral cortex and Purkinje cells of the cerebellum have
been reported to express SAA1 mRNA in normal human
brain [36]. However, non-neuronal SAA1 mRNA expres-
sion occurs, in CNS, in glial cell populations, and its
synthesis is stimulated by TNF-α, lipopolysaccaride, and
exogenous recombinant human Apo-SAA [22]. This evi-
dence suggests that the increased SAA1 mRNA in the
brain areas of EAE mice could be produced by activated
glial cells, including oligodendrocytes. In line with this
hypothesis, in the brains of patients with neurologically
confirmed MS, an intense immunohistochemical stain-
ing of SAA is associated to the myelin sheaths of axons
in the affected areas [37]. Moreover, PEALut has been
shown to reduce SAA1 mRNA in OPCs after TNF-α
treatment [22]. However, the possibility of a neuronal in-
crease or a synthesis of SAA1 mRNA by immune cells
recruited from periphery cannot be ruled out.
Many pro- and anti-inflammatory signals and pro-
resolving circuits converge on a group of receptors that
integrate contrasting cues to determine the course of in-
flammation. Among these receptors, we report that the
mRNA of receptors CD137, CD3-γ, CTR-ζ chain, TLR2,
Fpr2, and CB2 was increased in the brain areas of
MOG35-55, mainly on 14 PID, when clinical symptoms
were well established. Their expression was regulated by
PEALut administration. All these receptors are known
to be linked, with specific functions, to inflammatory re-
sponse; however, little is known about their temporal
profiles in the brainstem and cerebellum of mice immu-
nized with MOG35-55 peptide. The costimulatory mol-
ecule CD137 (4-1BB, TNFRSF9), a member of the TNF
receptor superfamily, is critical for both the induction
and effector phase of EAE. CD137 and CD137 ligands
(CD137L, 4-1BB ligand, TNFS9) increase in serum
and CSF of MS patients [38]. In addition, mRNA
CD137 has been reported to increase in activated
memory TMOG cells and its transcription regulated
by non-psychoactive cannabinoid, cannabidiol [39].
The reduction in CD137 mRNA expression, induced
by PEALut, might be also related to activated T cells.
The data sustain the idea that manipulation ofcostimulatory signals might represent an important
mechanism to inhibit immune activation.
The possibility of PEALut to influence T cell activation
and/or infiltration is also suggested from its ability to re-
duce the expression of the CD3-γ and TCR-ζ chain, two
transcripts of the TCR signal-transduction complex.
PEALut effects on T cell markers suggest that less T cells
infiltrate the CNS, and therefore the autoimmune re-
sponse may have been inhibited at peripheral sites rather
than a central sites.
As far as TLR2 evaluation in EAE models are con-
cerned, a previous in situ hybritization study reported a
positive staining of TLR2, mainly across meninges, on
10 PID as well as a robust expression in cerebral par-
enchima in several brain regions, including the medulla
and cerebellum, 3 weeks after the MOG35-55
immunization, when animals showed severe clinical
symptoms [40]. Our results confirm the increase of
TLR2 mRNA expression in connection with clinical
symptom presence; nevertheless, the highest expression
was observed on 14 PID in both the brainstem and cere-
bellum. Since dual labeling performed in previous study
[40] provided the anatomical evidence that microglia/
macrophages were the cells expressing TLR2 in the
brain of EAE mice, the decrease in TLR2 mRNA elicited
by PEALut confirms that microglia are one of TLR2 tar-
gets to reduce neuroinflammation. A further receptor
expressed by immune cells is the Fpr2. We report, for
the first time, a marked increase of Fpr2 mRNA in the
brainstem and cerebellum of mice immunized with
MOG35-55 on 14 PID and an important reduction elic-
ited by PEALut treatment. Fpr2 is a G protein-coupled
receptor functionally expressed on immune cells, includ-
ing mast cells, microglia, and epithelial cells, that trans-
duces signals from lipoxin A4, annexin A1, and SAA to
regulate inflammation and its resolution [41, 42]. Fpr2
ligand-specific interactions are able to induce either pro-
inflammatory or proresolution/anti-inflammatory effects.
In conditions associated to CNS damage such as the
hemicerebellectomy, Fpr2 protein level was significant
upregulated in secondary inflammatory damage phase
[43]. Our results show that an upregulation in Fpr2 also
occurs in experimental models of MS and that its regu-
lation with PEALut might trigger the resolution of
MOG35-55-induced inflammation. The finding that PEA-
Lut also limits MOG35-55-induced increase of CB2
mRNA also argue for a promotion of inflammation reso-
lution induced by the composite. In CNS, the expression
of CB2 receptors is mainly related to the activation state
of microglia and upregulation of CB2 receptors has been
associated with a restoration of tissue homeostasis in
pathological neuroinflammatory conditions [44]. On the
other hand, CB2 agonists include endogenous bioactive
lipids such as endocannabinoids that are well
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antly, the ability of PEA to enhance endocannabinoid
tone is well known [46].The data of this report suggest
that PEALut might also enhance endocannabinoid tone.
In contrast to CB2 gene expression, we did not find any
change in the CB1 receptor gene expression. In our
knowledge, this is the first time that the CB1 gene is
evaluated in MOG35-55-EAE model. Previous reports
showed a decrease in CB1 receptors in the monophasic
model of EAE in rats that was restricted to the basal
ganglia and cortical structures [47]. Thereafter, a moder-
ate decrease in the density of CB1 receptors was de-
scribed in the caudate–putamen during the acute phase
of chronic relapsing EAE while a more marked extent in
the chronic phase [48]. This evidence shows that the al-
teration of CB1 are region-dependent and become more
pronounced during the chronic phase of the disease.
Our results are in line with previous studies: in fact, the
MOG35-55 immunization condition used results in an
acute monophasic EAE, with a moderate severity of
neurological score.
A limitation of the present study relates and concerns
the lack of information on the protein levels correspond-
ing to the upregulated genes. In our previous study,
PEALut was found to stimulate both the MBP gene ex-
pression alongside with the MBP [20]. Unfortunately, in
the EAE model employed, in both the brainstem and
cerebellum, we did not observe any change in genes co-
difying myelin proteins at any time (data not shown).
For this reason, we could not investigate the in vivo ef-
fect of PEALut on gene expression and protein levels of
myelin proteins, as we had done in in vitro studies [20].
In the present study, we also scheduled to measure
TNF-α protein with ELISA in the brainstem at 28 PID.
At this time, unlike to what we had thought, both gene
expression and protein levels return to basal levels in
both MOG-Veh and PEALut-treated groups.Conclusions
The results reported here demonstrate that PEALut re-
duced the severity of clinical signs in the MOG35-55
model of EAE throughout a multitude of anti-
inflammatory signals and pro-resolving circuits. The re-
sults reported do not clarify whether PEALut might also
be useful to reduce the demyelination associated with
MS; in fact, the experimental conditions adopted and
the methods used did not allow the observation of de-
myelinating processes. The use of demyelination models
independently of immune attack such as the cuprizone
demyelination model will be more suitable to verify
whether PEALut facilitates the development of OPCs
in vivo and modulate the expression of different myelin
proteins as observed in vitro [20, 21].Abbreviations
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